Home
This site is intended for healthcare professionals

PMG Academy | Advancing Clinical Expertise: Optimizing Longitudinal Management

Share

Description

This activity is supported by an independent education grant from ArgenX. This online education program has been designed for healthcare professionals in the United States.

Managing Pediatric Myasthenia Gravis (PMG) requires balancing effective disease control against the long-term risks of immunosuppression in a developing child. Led by Dr. John Brandsema, this session provides practical strategies to individualize longitudinal care—guiding clinicians through stepwise immunotherapy, surgical considerations, functional outcome tracking, and structured transition planning.

Session Highlights

  • Balancing Immunotherapy & Steroid Stewardship: Define realistic treatment goals—such as minimal manifestation status—while minimizing cumulative corticosteroid exposure through the early introduction of steroid-sparing agents tailored to pediatric risks.
  • Crisis Management & Rescue Protocols: Recognize early warning signs of respiratory and bulbar decline, utilizing rescue therapies like IVIG or plasma exchange and pediatric intensive care support when rapid escalation is required.
  • Thymectomy Timing & Candidacy: Navigate surgical decision-making based on age, antibody status, and phenotype, identifying postpubertal patients with AChR-positive generalized PMG as the strongest candidates.
  • Longitudinal Monitoring & Adult Transition: Address the lack of standardized pediatric clinical outcome measures by tracking patient-centered daily function, planning cautious therapy de-escalation, and preparing adolescents early for transfer to adult care.

Prefer to read? See our Key Clinical Summary Here.

Target Audience

This program is designed for healthcare professionals involved in the diagnosis, treatment, and longitudinal management of pediatric patients with pediatric myasthenia gravis (PMG). Relevant clinicians include pediatric and general neurologists, neuromuscular specialists, pediatricians, and advanced practice providers, including nurse practitioners and physician assistants.

Faculty

Dr. John Brandsema, MD, is an Attending Physician in Neurology at Children’s Hospital of Philadelphia, specializing in pediatric neuromuscular disorders. He trained in pediatric neurology at The Hospital for Sick Children in Toronto and completed a neuromuscular medicine fellowship at Harvard Medical School and Massachusetts General Hospital. His research focuses on novel targeted therapies for rare neuromuscular disorders.

Disclosures

Partners for Advancing Clinical Education (Partners) requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated according to Partners policies. Others involved in the planning of this activity have no relevant financial relationships.

Dr John Brandsema has the following relevant financial relationships: Consultant; Alexion, Argenx, Audentes, AveXis/ Novartis Biogen, Catalyst, CSL Behring, Cytokinetics, Dyne, Edgewise, Entrada, Fibrogen, Fortress, Genentech/Roche, ITF, Janssen, Johnson and Johnson, Lexicon, Marathon, Mesoblast, Momenta, NS Pharma, Percheron, Pfizer, PTC Therapeutics, RegenxBio, Sarepta, Scholar Rock, Solid, Takeda, WaVe. Speaker; AveXis and Biogen. Medical Advisory Council; Cure SMA. Site Investigator Clinical Trials; Alexion, Astellas, Argenx, AveXis/Novartis, Biogen, Biohaven, Catabasis, Catalyst, CSL Behring, Cytokinetics, Dyne, Fibrogen, Genentech/Roche, Ionis, Italfarmaco, Lilly, Janssen, Octapharma, Pfizer, PTC Therapeutics, RegenxBio, Sarepta, Scholar Rock, Solid, Summit, WaVe.

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by Partners for Advancing Clinical Education (Partners) and MedAll. Partners is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Education

Partners designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Professional Development

The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 0.5 ANCC contact hours.

Pharmacy Continuing Education

Partners designates this continuing education activity for 0.5 contact hour(s) (0.5 CEUs) of the Accreditation Council for Pharmacy Education.

Universal Activity Number - JA4008073-9999-26-366-H01-P

Type of Activity: Application

PA Continuing Medical Education

Partners has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.5 AAPA Category 1 CME credits. Approval is valid until October 15th 2027. PAs should only claim credit commensurate with the extent of their participation.

Interprofessional Continuing Education

This activity was planned by and for the healthcare team, and learners will receive 0.5 Interprofessional Continuing Education (IPCE) credit for learning and change.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

This continuing education activity is active starting October 22nd 2026, and will expire on October 15th 2027.

Estimated time to complete this activity: 30 Minutes

Learning objectives

By the end of this educational program HCP's should be better able to:

  1. Recognize and accurately diagnose JMG through timely evaluation of pediatric patients with suspected neuromuscular junction disorders:

Differentiate JMG from congenital myasthenic syndromes, transient myasthenia, and other pediatric neuromuscular conditions with overlapping clinical presentations. Interpret serologic, electrophysiologic, and clinical findings to support diagnosis in atypical or seronegative presentations. Implement appropriate referral and diagnostic pathways to reduce delays in diagnosis and treatment initiation.

  1. Individualize treatment planning and longitudinal management strategies for pediatric patients with JMG across the disease continuum:

Apply patient-specific factors, including age at onset, disease phenotype, symptom burden, and treatment response, to guide management decisions. Monitor disease progression, treatment effectiveness, and evolving care needs to support timely treatment optimization and shared decision-making. Integrate transition planning and multidisciplinary care approaches to support continuity of management from pediatric to adult services.

  1. Incorporate emerging targeted therapies into evidence-informed treatment planning for patients with JMG:

Evaluate the mechanisms of action, clinical evidence, and potential role of emerging targeted therapies within the evolving JMG treatment landscape. Identify patients who may be appropriate candidates for targeted therapeutic approaches based on disease characteristics and treatment goals. Apply emerging evidence to support individualized treatment selection, sequencing, and long-term management decisions in clinical practice.

Similar communities

View all

Similar events and on demand videos

Computer generated transcript

Warning!
The following transcript was generated automatically from the content and has not been checked or corrected manually.

It's a pleasure to be with you today to talk about optimizing longitudinal management of pediatric myasthenia. Here is our first polling question. A 13-year-old with acetylcholine receptor-positive generalized pediatric myasthenia remains symptomatic after 8 weeks of pyridostigmine. He has ptosis, lunchtime onwards fatigue, and withdrawal from soccer. Weakness is predominantly limb axial, with only mild occasional. nasal speech. He's MGFA class 2A. What is the most appropriate next step? Would you A, increase the pyridostigmine to the maximum tolerated dose and review in 3 months, B, add a corticosteroid, considering a steroid sparing agent early if prolonged treatment is likely, C, refer for thymectomy before starting immunotherapy, D, start maintenance IVIG, or E, start a complement inhibitor. I will come back to the answer to this question later in the presentation. But let's start first with a case here again. Uh, this is a 13-year-old named Aidan. 5 months ago in class, he began dropping his head and struggling on the stairs. He was investigated for chronic fatigue, then for a muscle disorder. Acetylcholine receptor antibodies are strongly positive when tested. He had electromyography with repetitive nerve stimulation showing a Sacramental response and chest CT showed no thymoma. Um, he is MGFA class 2A with predominantly fatigueable neck and proximal limb weakness and only occasional mild, uh, nasal speech. And so you can see on the timeline here that he had about a 5-month odyssey before receiving his diagnosis of JMG. Um, some of the things to consider in discussing this case are that it is quite common to have a period of time where there's diagnostic uncertainty for people presenting with symptoms with myasthenia. Um, there are many other overlapping disorders that can have similar issues with weakness. Another issue that some Uh, run into is that the symptoms fluctuate quite a bit and they may be assessed at a time when they're relatively more or less symptomatic than other times that they're assessed, which confuses people who are trying to, um, come up with a differential diagnosis sometimes. Um, he is right in that pre-pubertal age, um, where other factors start to become complicated in terms of pediatric care going through puberty and starting to develop a sense of individual identity. Um, and, um, this can be complicated when also trying to adjust to, uh, chronic, uh, illness at the same time. Also, growth is very important to consider at this period because if we start medications that have an impact on growth trajectory, it could significantly impact his um pubertal experience and sometimes even delay onset of puberty with some of our medicines. Um, so when we're trying to treat pediatric myasthenia, um, our goal is the same as it is in any myasthenic patient, which is that we want symptoms to be reduced as much as possible, um, but not at the cost of having more side effects from the immunosuppression, um, than we're seeing benefit. And so finding that, uh, palette of things that is tailored to the individual often takes some trial and error. It So, um, can change over time because myasthenia is such a fluctuating disease where you can have a high symptom burden at one time of the year or one time of day even, and then another time may be very different. Um, so we have to tailor the approach to what's going on for the individual. And sometimes things change in their life, like additional stressors or other things that can make management more complex, even when they were previously. doing well. Um, our first line is usually pyridostigmine, which is a symptomatic treatment. And so we boost acetylcholine and hope that, um, the weakness symptoms will be lessened with that. Um, it does involve a fairly frequent dosing. There is a long-acting form that we can use for people, um, that might have issues first thing in the morning and would take it right before bed, or if they are having issues with breathing during sleep. Um, once we get past pyridostigmine, our next line is usually immunotherapy, um, with corticosteroids as a start. Although there's, of course, many, um, side effects associated with corticosteroids. Therefore, a steroid-sparing agent would be considered early when prolonged treatment is likely by most providers. Um, this would include things like azathioprine or mycopheno. Mofetil, methotrexate, tacrolimus, these all have data in myasthenia. Um, sometimes, um, when we're hoping to minimize, um, the steroid toxicity or we're not having a sufficient response to prednisone treatment, uh, we go to infusions such as rituximab or maintenance, uh, immunoglobulin. Um, but IVIG and plasma exchange are traditionally thought of as rescue therapies and bridging therapies, uh, where they may not be indefinite. Um, there are patients who do require maintenance IVIG or plasma exchange for management, however. And then, um, thymectomy is another consideration which we'll get into, um, later. The presentation. And, uh, finally, we have the new targeted approaches where we either, um, inhibit complement or, um, block the neonatal receptor or IgG, um, to, um, have a rapid response, um, to, uh, uh, symptom, uh, burden is the hope. So when we think about corticosteroids, um, the benefit is that it is effective and fast. We usually do not start at a high dose immediately in myasthenia because we can see a worsening of weakness before the weakness starts to improve, um, with higher. Dose steroids. So, uh, my general practice is to start low and go up gradually if we have the ability to do that relative to symptom burden. Um, they're also inexpensive, um, but of course, there's a very long list of potential side effects. In the short term, the Issues that tend to arise are behavior issues in children, um, or the increased appetite and weight gain with changes in habitus because of that, that are distressing to patients cosmetically. Um, the longer-term issues that we run into if we need steroids for extended periods of time are changes in growth, um, and also bone health effects where we have to be very careful about also including Vitamin D supplementation and sometimes other Bone health targeted approaches if we're running into issues. We can very rarely um see issues with um hyperglycemia and even diabetes developing, but that's more likely to be an adult issue than a pediatric one in my experience. Um, and cataracts on the eyes are also known to be an issue in the long term with, um, steroid use. So we really want to use the lowest effective dose, um, constantly modify our approach if we're seeing a difference in symptom burden to use the minimum amount possible, um, and monitor growth, BP, glucose, uh, bone health, and And, um, have the eyes followed by an ophthalmologist if we're needing high doses of steroids for long periods of time. Um, there is a, a critical period early on to watch for some of these issues as they start, and then the rest of it is more chronic and can be monitored on a less frequent basis, such as annually. When we're using steroid sparing agents, um, we have many different choices, and this really can depend on patient preference and provider preference in terms of which we might consider. The general theme of all of them is that they will further suppress the immune system and so we have to be more careful about infectious symptoms and new symptoms, um, getting evaluated with a lower threshold than we would in the average child, um, such as fever with, uh, uh, explained source or, um, upper respiratory. symptoms that are more complex than would be typical because we really can get an infection anywhere in the body when on these medications. Another issue is that they take a while to be effective, anywhere from, um, an effect being seen within 1 month to 3 months in the best case scenario, but sometimes up to 6 or even 12 months in some patients before you really start to see a benefit from your regular, um, daily medication with a medicine like azathioprine or mycophen. Phenolate. Um, in head to head comparisons, in general, mycophenolate tends to work a little bit more quickly in some of the cumulative data, um, but not by much. Um, and, um, there is monitoring required with all of these because they have a tendency to affect liver function in some patients, um, bone marrow function in some patients leading to cytopenias, and also, um, renal function in the case of tacrolimus, along with magnesium issues sometimes. Um, so all of these, um, require some level of lab work, although the frequency of doing this is, um, variable by provider. Um, and also based on what's going on in the patient. Um, the teratogenicity of mycophenolates especially is very important to discuss with adolescent female patients that are being treated that it's really important.